Evaluation of the efficacy of novel therapeutics for potential treatment of Alzheimer's disease (AD) requires an animal model that develops age-related cognitive deficits reproducibly between independent groups of investigators. Herein we assessed comparative temporal changes in spatial memory function in two commercially available transgenic mouse models of AD using the Morris water maze (MWM), incorporating both visible and hidden platform training. Individual cohorts of cDNA-based line 85'-derived double-transgenic mice coexpressing the Swedish' mutation of amyloid precursor protein (APPSwe) and the presenillin 1 (PS1) dE9' mutation were assessed in the MWM at mean ages of 3.6, 9.3 and 14.8months. We found significant deficits in spatial memory retention in APPSwe/PS1dE9 mice aged 3.6months and robust deficits in spatial memory acquisition and retention in APPSwe/PS1dE9 mice aged 9.3months, with a further significant decline by age 14.8months. -Amyloid deposits were present in brain sections by 7.25months of age. In contrast, MWM studies with individual cohorts (aged 4-21months) of single-transgenic genomic-based APPSwe mice expressing APPSwe on a yeast artificial chromosomal (YAC) construct showed no significant deficits in spatial memory acquisition until 21months of age. There were no significant deficits in spatial memory retention up to 21months of age and -amyloid deposits were not present in brain sections up to 24months of age. These data, generated using comprehensive study designs, show that APPSwe/PS1dE9 but not APPSwe YAC mice appear to provide a suitably robust model of AD for efficacy assessment of novel AD treatments in development.
|Number of pages||9|
|Journal||Clinical and Experimental Pharmacology and Physiology|
|Publication status||Published - 2014|